(SeaPRwire) –
ERAPs (ERAP1 and ERAP2) are becoming recognized as promising therapeutic targets linked to various autoimmune conditions. Genomics will compile the most extensive genetic dataset to assess how variations in ERAP genes affect a person’s susceptibility to multiple autoimmune diseases. The findings will be applied to enhance Greywolf Therapeutics’ portfolio of autoimmune disease treatments. OXFORD, England, April 29, 2026 — Genomics, a science-led … Continue reading “Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases”
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.